Primary versus secondary gliosarcoma: a systematic review and meta-analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-06-29

AUTHORS

Huy Gia Vuong, Ian F. Dunn

ABSTRACT

IntroductionGliosarcomas are extremely rare malignant brain tumors, which can be classified as primary gliosarcoma (PGS) if the tumors arise de novo or secondary gliosarcoma (SGS) in patients who had previously been treated for glioblastoma. Given their rarity, it is unclear if PGS is clinically and genetically different from SGS. This meta-analysis aimed to investigate the clinicopathological features, prognostic survivals, and molecular profiles of these rare tumors. MethodsWe searched PubMed and Web of Science for relevant studies. Odds ratio (OR), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model.ResultsWe included eight studies with 239 PGS and 79 SGS for meta-analyses. Compared to PGS, SGS occurred at a younger age and had lower rates of gross total resection and radiation therapy. Bevacizumab was more commonly administered in SGS. SGS patients had a significantly worse PFS (HR 0.60; 95% CI 0.40–0.89) and OS (HR 0.46; 95% CI 0.31–0.68) in comparison to PGS. The incidences of EGFR mutation, IDH mutation, and MGMT methylation were not statistically different between PGS and SGS.ConclusionOur results demonstrated that PGS and SGS had distinct clinicopathological profiles and prognoses but shared similar genetic profiles. This study facilitates our understanding of how these two malignant brain tumors behave clinically, but future studies will be required to elucidate the genetic pathways of PGS and SGS. More... »

PAGES

195-200

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-022-04057-w

DOI

http://dx.doi.org/10.1007/s11060-022-04057-w

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149066928

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35768633


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gliosarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Neurosurgery, Oklahoma University Health Sciences Center, 73104, Oklahoma City, OK, USA", 
          "id": "http://www.grid.ac/institutes/grid.266902.9", 
          "name": [
            "Department of Neurosurgery, Oklahoma University Health Sciences Center, 73104, Oklahoma City, OK, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vuong", 
        "givenName": "Huy Gia", 
        "id": "sg:person.01272360127.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272360127.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neurosurgery, Oklahoma University Health Sciences Center, 73104, Oklahoma City, OK, USA", 
          "id": "http://www.grid.ac/institutes/grid.266902.9", 
          "name": [
            "Department of Neurosurgery, Oklahoma University Health Sciences Center, 73104, Oklahoma City, OK, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dunn", 
        "givenName": "Ian F.", 
        "id": "sg:person.01220016014.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220016014.50"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11060-011-0790-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565820", 
          "https://doi.org/10.1007/s11060-011-0790-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-015-1930-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008072204", 
          "https://doi.org/10.1007/s11060-015-1930-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-020-07364-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1131075113", 
          "https://doi.org/10.1186/s12885-020-07364-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41598-021-97454-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1140996406", 
          "https://doi.org/10.1038/s41598-021-97454-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1745-6215-8-16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052599734", 
          "https://doi.org/10.1186/1745-6215-8-16"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-012-1029-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045981566", 
          "https://doi.org/10.1007/s11060-012-1029-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-017-2718-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099741572", 
          "https://doi.org/10.1007/s11060-017-2718-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-06-29", 
    "datePublishedReg": "2022-06-29", 
    "description": "IntroductionGliosarcomas are extremely rare malignant brain tumors, which can be classified as primary gliosarcoma (PGS) if the tumors arise de novo or secondary gliosarcoma (SGS) in patients who had previously been treated for glioblastoma. Given their rarity, it is unclear if PGS is clinically and genetically different from SGS. This meta-analysis aimed to investigate the clinicopathological features, prognostic survivals, and molecular profiles of these rare tumors.\nMethodsWe searched PubMed and Web of Science for relevant studies. Odds ratio (OR), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model.ResultsWe included eight studies with 239 PGS and 79 SGS for meta-analyses. Compared to PGS, SGS occurred at a younger age and had lower rates of gross total resection and radiation therapy. Bevacizumab was more commonly administered in SGS. SGS patients had a significantly worse PFS (HR 0.60; 95% CI 0.40\u20130.89) and OS (HR 0.46; 95% CI 0.31\u20130.68) in comparison to PGS. The incidences of EGFR mutation, IDH mutation, and MGMT methylation were not statistically different between PGS and SGS.ConclusionOur results demonstrated that PGS and SGS had distinct clinicopathological profiles and prognoses but shared similar genetic profiles. This study facilitates our understanding of how these two malignant brain tumors behave clinically, but future studies will be required to elucidate the genetic pathways of PGS and SGS.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-022-04057-w", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "159"
      }
    ], 
    "keywords": [
      "secondary gliosarcoma", 
      "primary gliosarcoma", 
      "malignant brain tumors", 
      "hazard ratio", 
      "odds ratio", 
      "brain tumors", 
      "rare malignant brain tumor", 
      "distinct clinicopathological profile", 
      "gross total resection", 
      "confidence intervals", 
      "random-effects model", 
      "Web of Science", 
      "prognostic survival", 
      "total resection", 
      "worse PFS", 
      "clinicopathological profile", 
      "clinicopathological features", 
      "rare tumor", 
      "EGFR mutations", 
      "radiation therapy", 
      "systematic review", 
      "SGS patients", 
      "younger age", 
      "ConclusionOur results", 
      "tumors", 
      "MGMT methylation", 
      "IDH mutations", 
      "gliosarcoma", 
      "molecular profile", 
      "relevant studies", 
      "similar genetic profiles", 
      "patients", 
      "lower rates", 
      "genetic profile", 
      "future studies", 
      "de novo", 
      "bevacizumab", 
      "resection", 
      "prognosis", 
      "PFS", 
      "therapy", 
      "PubMed", 
      "genetic pathways", 
      "MethodsWe", 
      "incidence", 
      "mutations", 
      "study", 
      "glioblastoma", 
      "ResultsWe", 
      "survival", 
      "age", 
      "rarity", 
      "profile", 
      "OS", 
      "review", 
      "pathway", 
      "novo", 
      "interval", 
      "ratio", 
      "rate", 
      "methylation", 
      "comparison", 
      "features", 
      "Web", 
      "results", 
      "understanding", 
      "model", 
      "science"
    ], 
    "name": "Primary versus secondary gliosarcoma: a systematic review and meta-analysis", 
    "pagination": "195-200", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149066928"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-022-04057-w"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35768633"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-022-04057-w", 
      "https://app.dimensions.ai/details/publication/pub.1149066928"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_947.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-022-04057-w"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04057-w'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04057-w'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04057-w'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-022-04057-w'


 

This table displays all metadata directly associated to this object as RDF triples.

188 TRIPLES      21 PREDICATES      106 URIs      91 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-022-04057-w schema:about N09257d01460d445699441eaa9e4b6e72
2 N0e2eaf45a7b34a3ab972262796c52340
3 N58eeb61d13c54683ab71f16c40c96472
4 N6f3bbf19fd5f4acea1368b9239458da6
5 N88f8c65db51a4e06b7c8c272f9318b78
6 Nb41642c5adaa464fa9df79d62bae7f6f
7 anzsrc-for:11
8 anzsrc-for:1112
9 schema:author N9ecb848c29b94471ae0e76a21fa8edba
10 schema:citation sg:pub.10.1007/s11060-011-0790-3
11 sg:pub.10.1007/s11060-012-1029-7
12 sg:pub.10.1007/s11060-015-1930-y
13 sg:pub.10.1007/s11060-017-2718-z
14 sg:pub.10.1038/s41598-021-97454-6
15 sg:pub.10.1186/1745-6215-8-16
16 sg:pub.10.1186/s12885-020-07364-5
17 schema:datePublished 2022-06-29
18 schema:datePublishedReg 2022-06-29
19 schema:description IntroductionGliosarcomas are extremely rare malignant brain tumors, which can be classified as primary gliosarcoma (PGS) if the tumors arise de novo or secondary gliosarcoma (SGS) in patients who had previously been treated for glioblastoma. Given their rarity, it is unclear if PGS is clinically and genetically different from SGS. This meta-analysis aimed to investigate the clinicopathological features, prognostic survivals, and molecular profiles of these rare tumors. MethodsWe searched PubMed and Web of Science for relevant studies. Odds ratio (OR), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model.ResultsWe included eight studies with 239 PGS and 79 SGS for meta-analyses. Compared to PGS, SGS occurred at a younger age and had lower rates of gross total resection and radiation therapy. Bevacizumab was more commonly administered in SGS. SGS patients had a significantly worse PFS (HR 0.60; 95% CI 0.40–0.89) and OS (HR 0.46; 95% CI 0.31–0.68) in comparison to PGS. The incidences of EGFR mutation, IDH mutation, and MGMT methylation were not statistically different between PGS and SGS.ConclusionOur results demonstrated that PGS and SGS had distinct clinicopathological profiles and prognoses but shared similar genetic profiles. This study facilitates our understanding of how these two malignant brain tumors behave clinically, but future studies will be required to elucidate the genetic pathways of PGS and SGS.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N3875dd82223348e497d9fa463d6d634a
23 N8fbf20f712cf40689a586ef0a95bef5c
24 sg:journal.1094205
25 schema:keywords ConclusionOur results
26 EGFR mutations
27 IDH mutations
28 MGMT methylation
29 MethodsWe
30 OS
31 PFS
32 PubMed
33 ResultsWe
34 SGS patients
35 Web
36 Web of Science
37 age
38 bevacizumab
39 brain tumors
40 clinicopathological features
41 clinicopathological profile
42 comparison
43 confidence intervals
44 de novo
45 distinct clinicopathological profile
46 features
47 future studies
48 genetic pathways
49 genetic profile
50 glioblastoma
51 gliosarcoma
52 gross total resection
53 hazard ratio
54 incidence
55 interval
56 lower rates
57 malignant brain tumors
58 methylation
59 model
60 molecular profile
61 mutations
62 novo
63 odds ratio
64 pathway
65 patients
66 primary gliosarcoma
67 profile
68 prognosis
69 prognostic survival
70 radiation therapy
71 random-effects model
72 rare malignant brain tumor
73 rare tumor
74 rarity
75 rate
76 ratio
77 relevant studies
78 resection
79 results
80 review
81 science
82 secondary gliosarcoma
83 similar genetic profiles
84 study
85 survival
86 systematic review
87 therapy
88 total resection
89 tumors
90 understanding
91 worse PFS
92 younger age
93 schema:name Primary versus secondary gliosarcoma: a systematic review and meta-analysis
94 schema:pagination 195-200
95 schema:productId N24ba69afa4dd4324832f105e1d98e692
96 N77238e0710db4b61a9151e69e9d54ce7
97 Naca84c11948e4cb79a8577bdb3c931da
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149066928
99 https://doi.org/10.1007/s11060-022-04057-w
100 schema:sdDatePublished 2022-12-01T06:44
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N629985e70e7945708a215a3a42f0a482
103 schema:url https://doi.org/10.1007/s11060-022-04057-w
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N09257d01460d445699441eaa9e4b6e72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Mutation
109 rdf:type schema:DefinedTerm
110 N0e2eaf45a7b34a3ab972262796c52340 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Glioblastoma
112 rdf:type schema:DefinedTerm
113 N24ba69afa4dd4324832f105e1d98e692 schema:name pubmed_id
114 schema:value 35768633
115 rdf:type schema:PropertyValue
116 N3875dd82223348e497d9fa463d6d634a schema:issueNumber 1
117 rdf:type schema:PublicationIssue
118 N58eeb61d13c54683ab71f16c40c96472 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Humans
120 rdf:type schema:DefinedTerm
121 N629985e70e7945708a215a3a42f0a482 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N6f3bbf19fd5f4acea1368b9239458da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Brain Neoplasms
125 rdf:type schema:DefinedTerm
126 N77238e0710db4b61a9151e69e9d54ce7 schema:name doi
127 schema:value 10.1007/s11060-022-04057-w
128 rdf:type schema:PropertyValue
129 N88f8c65db51a4e06b7c8c272f9318b78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Gliosarcoma
131 rdf:type schema:DefinedTerm
132 N8fbf20f712cf40689a586ef0a95bef5c schema:volumeNumber 159
133 rdf:type schema:PublicationVolume
134 N9ecb848c29b94471ae0e76a21fa8edba rdf:first sg:person.01272360127.93
135 rdf:rest Nfe965699a30448cab76460652f2268fe
136 Naca84c11948e4cb79a8577bdb3c931da schema:name dimensions_id
137 schema:value pub.1149066928
138 rdf:type schema:PropertyValue
139 Nb41642c5adaa464fa9df79d62bae7f6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Prognosis
141 rdf:type schema:DefinedTerm
142 Nfe965699a30448cab76460652f2268fe rdf:first sg:person.01220016014.50
143 rdf:rest rdf:nil
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
148 schema:name Oncology and Carcinogenesis
149 rdf:type schema:DefinedTerm
150 sg:journal.1094205 schema:issn 0167-594X
151 1573-7373
152 schema:name Journal of Neuro-Oncology
153 schema:publisher Springer Nature
154 rdf:type schema:Periodical
155 sg:person.01220016014.50 schema:affiliation grid-institutes:grid.266902.9
156 schema:familyName Dunn
157 schema:givenName Ian F.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220016014.50
159 rdf:type schema:Person
160 sg:person.01272360127.93 schema:affiliation grid-institutes:grid.266902.9
161 schema:familyName Vuong
162 schema:givenName Huy Gia
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272360127.93
164 rdf:type schema:Person
165 sg:pub.10.1007/s11060-011-0790-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565820
166 https://doi.org/10.1007/s11060-011-0790-3
167 rdf:type schema:CreativeWork
168 sg:pub.10.1007/s11060-012-1029-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045981566
169 https://doi.org/10.1007/s11060-012-1029-7
170 rdf:type schema:CreativeWork
171 sg:pub.10.1007/s11060-015-1930-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1008072204
172 https://doi.org/10.1007/s11060-015-1930-y
173 rdf:type schema:CreativeWork
174 sg:pub.10.1007/s11060-017-2718-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1099741572
175 https://doi.org/10.1007/s11060-017-2718-z
176 rdf:type schema:CreativeWork
177 sg:pub.10.1038/s41598-021-97454-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140996406
178 https://doi.org/10.1038/s41598-021-97454-6
179 rdf:type schema:CreativeWork
180 sg:pub.10.1186/1745-6215-8-16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052599734
181 https://doi.org/10.1186/1745-6215-8-16
182 rdf:type schema:CreativeWork
183 sg:pub.10.1186/s12885-020-07364-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131075113
184 https://doi.org/10.1186/s12885-020-07364-5
185 rdf:type schema:CreativeWork
186 grid-institutes:grid.266902.9 schema:alternateName Department of Neurosurgery, Oklahoma University Health Sciences Center, 73104, Oklahoma City, OK, USA
187 schema:name Department of Neurosurgery, Oklahoma University Health Sciences Center, 73104, Oklahoma City, OK, USA
188 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...